Research Summary
Anti-obesity prescription drugs are medications specifically used to treat obesity, helping to reduce body weight through various mechanisms, typically for patients who cannot effectively lose weight through diet and exercise alone. These drugs may work by suppressing appetite, increasing metabolic rate, or blocking fat absorption. Common types of anti-obesity drugs include selective 5-HT2C receptor agonists, fat absorption inhibitors, and central nervous system suppressants. Anti-obesity drugs are usually prescribed under the guidance of a healthcare professional, as they may have side effects and require careful monitoring for potential drug interactions. In most cases, these medications need to be used in conjunction with a low-calorie diet and increased physical activity for optimal results. Additionally, certain anti-obesity drugs may be suitable for obese patients with comorbid conditions such as diabetes, hypertension, or high cholesterol, helping to manage these concurrent issues. However, anti-obesity medications are not intended as a long-term solution, and the core of weight management remains adopting a healthy lifestyle.
According to WENKH research statistics, the global Anti-Obesity Prescription Drugs market size will reach Million USD in 2026 and is projected to reach Million USD by 2033, with a CAGR of % (2026-2033). Among them, the Asia-Pacific Anti-Obesity Prescription Drugs market is undergoing rapid changes, reaching Million USD in 2026, accounting for approximately % of the global market share. It is projected to reach Million USD by 2033.
The global Anti-Obesity Prescription Drugs market is highly competitive, with key market players including F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme, etc. This report categorizes the competitive landscape of the global Anti-Obesity Prescription Drugs market into three tiers based on annual revenue, with the top three market players holding approximately % of the total market share.
This report provides an in-depth analysis of the global Anti-Obesity Prescription Drugs market, including market size, price trends, market status and future development prospects. It particularly focuses on the market share, product characteristics, pricing, sales revenue, and gross profit margin of major players in the global Anti-Obesity Prescription Drugs industry. Additionally, this report provides an in-depth analysis of the market status and future development trends of different product segments of Anti-Obesity Prescription Drugs and their downstream application fields.
In terms of data, this report includes a comprehensive time-series dataset. The historical data spans from 2021 to 2025, providing a solid foundation for analyzing past market trends. The year 2026 is used as a base year to accurately assess the current market landscape. Forecast data covers the period from 2027 to 2033, utilizing scientific analysis methods and models to offer forward-looking predictions and insights into the market's future development. This provides valuable reference information for industry participants and stakeholders.
The report covers regions and countries including North America, Europe, China, Asia Pacific (excluding China), Latin America, the Middle East, and Africa. It particularly focuses on the sales revenue of Anti-Obesity Prescription Drugs in these regions and countries, as well as the market share of key market players in each region. The report provides an in-depth analysis of the regional distribution and future development trends of the Anti-Obesity Prescription Drugs market. By considering local policies, this report evaluates the market prospects of Anti-Obesity Prescription Drugs in each region and country, aiming to help companies gain a comprehensive understanding of the industry characteristics and development potential in different regions, optimize regional business layout, and develop precise market strategies to achieve global development goals.
This report places a strong emphasis on data quality and reliability, utilizing diverse and extensive data sources to ensure the accuracy and validity of the information presented. Primary data collection involves multiple channels, including in-depth interviews with senior executives, industry experts, supply chain stakeholders, and end consumers. These interviews provide key insights into corporate strategic planning, industry policy interpretation, supply chain dynamics, and end-user experiences. Secondary data sources cover a wide range of authoritative statistics from government agencies, customs databases, industry associations, third-party paid databases, brokerage research reports, academic research findings, corporate annual reports, financial statements, real-time news updates, and relevant information from international organizations. These data sources serve as a solid foundation for verification and analysis.
Companies Covered
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Product Segment
Wegovy
Saxenda
Zepbound
Xenical
Others
Product Application
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Chapter Scope
Chapter 1: Product Statistical Scope, Product Segmentation Types and Downstream Applications, Overall Market Size, Current Status and Development Prospects
Chapter 2: Global Anti-Obesity Prescription Drugs Industry Chain Analysis
Chapter 3: Global Anti-Obesity Prescription Drugs Industry Environment Analysis and Porter's Five Forces Analysis
Chapter 4: Analysis of the Competitive Landscape of Major Companies in the Global Anti-Obesity Prescription Drugs Market (Market Share, Product Revenue Comparison, Tier Division, Corporate Expansion and M&A Trends)
Chapter 5: Analysis of Global Major Companies (Company Profiles, Product Features and Product Segment, Product Revenue, Product Average Price, Gross Profit Margin and Geographical Sales Share)
Chapter 6: Global Anti-Obesity Prescription Drugs Product Segment and Downstream Application Size Analysis and Major Regional Market Size Analysis
Chapter 7: North America Anti-Obesity Prescription Drugs Product Segment, Downstream Application, and Major Countries Market Size Analysis
Chapter 8: Europe Anti-Obesity Prescription Drugs Product Segment, Downstream Application, and Major Countries Market Size Analysis
Chapter 9: China Anti-Obesity Prescription Drugs Product Segment, Downstream Application, and Major Countries Market Size Analysis
Chapter 10: Asia Pacific (excluding China) Anti-Obesity Prescription Drugs Product Segment, Downstream Application, and Major Countries Market Size Analysis
Chapter 11: Latin America Anti-Obesity Prescription Drugs Product Segment, Downstream Application, and Major Countries Market Size Analysis
Chapter 12: Middle East and Africa Anti-Obesity Prescription Drugs Product Segment, Downstream Application, and Major Countries Market Size Analysis
Chapter 13: Research Conclusion
Chapter 14: Methodology and Data Source
Purpose and Value of the Report
Market Trend Insights: Analyze industry trends, market dynamics, and future growth potential to help companies forecast changes and develop strategic plans.
Competitive Landscape Analysis: Understand key players' revenue segmentation, strategies, market share, and business models to guide competitive decisions.
Investment Decision Support: Provide feasibility analysis through market size, growth rate, demand trends, and potential risks for informed investment decisions.
Target Customer and Demand Analysis: Examine consumer behavior, purchasing preferences, and pain points to optimize products and improve market penetration.
Policy and Regulatory Insights: Interpret relevant industry policies to ensure compliance and mitigate regulatory risks.
Business Model Optimization: Offer data-driven suggestions for enhancing business models and improving profitability.
Table of Contents
1 Anti-Obesity Prescription Drugs Market Overview
1.1 Product Definition Introduction
1.2 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis (2021-2033)
1.3 Anti-Obesity Prescription Drugs Market Status and Development Prospects
1.3.1 Anti-Obesity Prescription Drugs Market Status
1.3.2 Anti-Obesity Prescription Drugs Industry Development Prospects
1.4 Anti-Obesity Prescription Drugs Market Overview by Product Segment
1.4.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Segment: 2021 VS 2026 VS 2033
1.4.2 Wegovy
1.4.3 Saxenda
1.4.4 Zepbound
1.4.5 Xenical
1.4.6 Others
1.5 Anti-Obesity Prescription Drugs Market Overview by Product Application
1.5.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Application: 2021 VS 2026 VS 2033
1.5.2 Hospitals Pharmacies
1.5.3 Retail Pharmacies
1.5.4 E-commerce
2 Anti-Obesity Prescription Drugs Industry Supply Chain Analysis
2.1 Anti-Obesity Prescription Drugs Supply Chain
2.2 Anti-Obesity Prescription Drugs Midstream Suppliers
2.3 Anti-Obesity Prescription Drugs Downstream Customers
2.4 Anti-Obesity Prescription Drugs Sales Channel Analysis
3 Anti-Obesity Prescription Drugs Market Environment Analysis
3.1 Anti-Obesity Prescription Drugs Industry Policy Analysis
3.2 Anti-Obesity Prescription Drugs Emerging Technology Trends in the Industry
3.3 Anti-Obesity Prescription Drugs Restraining Factors Analysis
3.4 Anti-Obesity Prescription Drugs Market Porter's Five Forces Analysis
3.4.1 Competitive Rivalry
3.4.2 Threat of New Entrants
3.4.3 Bargaining Power of Suppliers
3.4.4 Bargaining Power of Buyers
3.4.5 Threat of Substitute Products or Services
4 Global Anti-Obesity Prescription Drugs Market Players Competition Landscape
4.1 Global Anti-Obesity Prescription Drugs Market Revenue by Key Players (2021-2026)
4.2 Global Anti-Obesity Prescription Drugs Market Position by Key Players
4.3 Global Key Players Headquarter and Key Area Served
4.4 Global Anti-Obesity Prescription Drugs Market Expansion and M&A Dynamic
5 In-depth Analysis of Key Players
5.1 F Hoffmann La Roche Ltd
5.1.1 F Hoffmann La Roche Ltd Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Features
5.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.1.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue by Product Segment
5.1.5 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue by Region
5.2 Orexigen Therapeutics
5.2.1 Orexigen Therapeutics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Features
5.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.2.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue by Product Segment
5.2.5 Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue by Region
5.3 Novo Nordisk A/s
5.3.1 Novo Nordisk A/s Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Features
5.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.3.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue by Product Segment
5.3.5 Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue by Region
5.4 Arena Pharmaceuticals
5.4.1 Arena Pharmaceuticals Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Features
5.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.4.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue by Product Segment
5.4.5 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue by Region
5.5 Glaxosmithkline
5.5.1 Glaxosmithkline Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Features
5.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.5.4 Glaxosmithkline Anti-Obesity Prescription Drugs Revenue by Product Segment
5.5.5 Glaxosmithkline Anti-Obesity Prescription Drugs Revenue by Region
5.6 Vivus
5.6.1 Vivus Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.6.2 Vivus Anti-Obesity Prescription Drugs Product Features
5.6.3 Vivus Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.6.4 Vivus Anti-Obesity Prescription Drugs Revenue by Product Segment
5.6.5 Vivus Anti-Obesity Prescription Drugs Revenue by Region
5.7 Boehringer Ingelheim
5.7.1 Boehringer Ingelheim Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Features
5.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.7.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue by Product Segment
5.7.5 Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue by Region
5.8 Alizyme
5.8.1 Alizyme Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.8.2 Alizyme Anti-Obesity Prescription Drugs Product Features
5.8.3 Alizyme Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.8.4 Alizyme Anti-Obesity Prescription Drugs Revenue by Product Segment
5.8.5 Alizyme Anti-Obesity Prescription Drugs Revenue by Region
6 Global Anti-Obesity Prescription Drugs Market Analysis by Regions, by Product Segment and Application
6.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast by Region: 2021 VS 2026 VS 2033
6.1.1 Global Anti-Obesity Prescription Drugs Market Revenue by Region (2021-2026)
6.1.2 Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Region (2027-2033)
6.2 Global Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
6.3 Global Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
7 North America Anti-Obesity Prescription Drugs Market Analysis
7.1 North America Anti-Obesity Prescription Drugs Market Prospects
7.1.1 North America Anti-Obesity Prescription Drugs Market Revenue and Growth Forecast by Countries (2021-2033)
7.1.2 U.S.
7.1.3 Canada
7.2 North America Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
7.3 North America Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
8 Europe Anti-Obesity Prescription Drugs Market Analysis
8.1 Europe Anti-Obesity Prescription Drugs Market Prospects
8.1.1 Europe Anti-Obesity Prescription Drugs Market Revenue and Growth Forecast by Countries (2021-2033)
8.1.2 Germany
8.1.3 France
8.1.4 United Kingdom
8.1.5 Italy
8.1.6 Spain
8.1.7 Benelux
8.2 Europe Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
8.3 Europe Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
9 China Anti-Obesity Prescription Drugs Market Analysis
9.1 China Anti-Obesity Prescription Drugs Market Prospects
9.2 China Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
9.3 China Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
10 Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Analysis
10.1 Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Prospects
10.1.1 Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Revenue and Growth Forecast by Countries (2021-2033)
10.1.2 Japan
10.1.3 South Korea
10.1.4 India
10.1.5 Southeast Asia
10.1.6 Australia
10.2 Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
10.3 Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
11 Latin America Anti-Obesity Prescription Drugs Market Analysis
11.1 Latin America Anti-Obesity Prescription Drugs Market Prospects
11.1.1 Latin America Anti-Obesity Prescription Drugs Revenue and Growth Forecast by Countries (2021-2033)
11.1.2 Mexico
11.1.3 Brazil
11.2 Latin America Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
11.3 Latin America Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
12 Middle East and Africa Anti-Obesity Prescription Drugs Market Analysis
12.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Prospects
12.1.1 Middle East and Africa Anti-Obesity Prescription Drugs Revenue and Growth Forecast by Countries (2021-2033)
12.1.2 Saudi Arabia
12.1.3 South Africa
12.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
12.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
13 Research Conclusion
14 Appendix
14.1 Methodology/Research Approach
14.2 Research Landscape
14.3 Research Benchmark and Hypothesis
14.4 Data Source
14.4.1 Primary Sources
14.4.2 Secondary Sources
14.5 Data Cross Validation
14.6 Disclaimer
Table 1：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Segment (2021 VS 2026 VS 2033) & (Million USD)
Table 2：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Application (2021 VS 2026 VS 2033) & (Million USD)
Table 3：Anti-Obesity Prescription Drugs Downstream Customers List
Table 4：Anti-Obesity Prescription Drugs Distributors/Dealers List
Table 5：Global Anti-Obesity Prescription Drugs Market Revenue by Key Players (2021-2026) & (Million USD)
Table 6：Global Anti-Obesity Prescription Drugs Market Position by Key Players
Table 7：Global Key Players Headquarter and Key Area Served
Table 8：Global Anti-Obesity Prescription Drugs Market Expansion and M&A Dynamic
Table 9：F Hoffmann La Roche Ltd Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 10：F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Features
Table 11：F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 12：F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 13：F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue by Region
Table 14：Orexigen Therapeutics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 15：Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Features
Table 16：Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 17：Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 18：Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue by Region
Table 19：Novo Nordisk A/s Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 20：Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Features
Table 21：Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 22：Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 23：Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue by Region
Table 24：Arena Pharmaceuticals Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 25：Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Features
Table 26：Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 27：Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 28：Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue by Region
Table 29：Glaxosmithkline Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 30：Glaxosmithkline Anti-Obesity Prescription Drugs Product Features
Table 31：Glaxosmithkline Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 32：Glaxosmithkline Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 33：Glaxosmithkline Anti-Obesity Prescription Drugs Revenue by Region
Table 34：Vivus Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 35：Vivus Anti-Obesity Prescription Drugs Product Features
Table 36：Vivus Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 37：Vivus Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 38：Vivus Anti-Obesity Prescription Drugs Revenue by Region
Table 39：Boehringer Ingelheim Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 40：Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Features
Table 41：Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 42：Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 43：Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue by Region
Table 44：Alizyme Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 45：Alizyme Anti-Obesity Prescription Drugs Product Features
Table 46：Alizyme Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 47：Alizyme Anti-Obesity Prescription Drugs Revenue by Product Segment
Table 48：Alizyme Anti-Obesity Prescription Drugs Revenue by Region
Table 49：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast by Region (2021 VS 2026 VS 2033) & (Million USD)
Table 50：Global Anti-Obesity Prescription Drugs Market Revenue by Region (2021-2026) & (Million USD)
Table 51：Global Anti-Obesity Prescription Drugs Market Share by Region (2021-2026)
Table 52：Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Region (2027-2033) & (Million USD)
Table 53：Global Anti-Obesity Prescription Drugs Market Share Forecast by Region (2027-2033)
Table 54：Global Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 55：Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 56：Global Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 57：Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 58：North America Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026) & (Million USD)
Table 59：North AmericaAnti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033) & (Million USD)
Table 60：North America Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 61：North America Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 62：North America Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 63：North America Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 64：Europe Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026) & (Million USD)
Table 65：Europe Anti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033) & (Million USD)
Table 66：Europe Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 67：Europe Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 68：Europe Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 69：Europe Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 70：China Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 71：China Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 72：China Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 73：China Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 74：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026) & (Million USD)
Table 75：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033) & (Million USD)
Table 76：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 77：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 78：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 79：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 80：Latin America Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026) & (Million USD)
Table 81：Latin America Anti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033) & (Million USD)
Table 82：Latin America Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 83：Latin America Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 84：Latin America Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 85：Latin America Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 86：Middle East and Africa Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026) & (Million USD)
Table 87：Middle East and Africa Anti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033) & (Million USD)
Table 88：Middle East and Africa Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 89：Middle East and Africa Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 90：Middle East and Africa Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 91：Middle East and Africa Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 92：Secondary Sources
Figure 1：Anti-Obesity Prescription Drugs Product Scope
Figure 2：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis (2021-2033) & (Million USD)
Figure 3：Global Anti-Obesity Prescription Drugs Product Segment Market Share (2026 & 2033)
Figure 4：Global Anti-Obesity Prescription Drugs Product Application Market Share (2026 & 2033)
Figure 5：Wegovy Product Scope
Figure 6：Saxenda Product Scope
Figure 7：Zepbound Product Scope
Figure 8：Xenical Product Scope
Figure 9：Others Product Scope
Figure 10：Hospitals Pharmacies Product Scope
Figure 11：Retail Pharmacies Product Scope
Figure 12：E-commerce Product Scope
Figure 13：Anti-Obesity Prescription Drugs Industrial Chain Framework
Figure 14：Global Anti-Obesity Prescription Drugs Market by Geographic Segmentation in 2026
Figure 15：Global Anti-Obesity Prescription Drugs Market Share by Region (2021 VS 2026)
Figure 16：North America Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 17：North America Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2026 VS 2033)
Figure 18：U.S. Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 19：Canada Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 20：Europe Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 21：Europe Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2026 VS 2033)
Figure 22：Germany Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 23：France Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 24：United Kingdom Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 25：Italy Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 26：Spain Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 27：Benelux Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 28：China Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 29：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 30：Asia Pacific (excl. China) Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2026 VS 2033)
Figure 31：Japan Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 32：South Korea Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 33：India Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 34：Southeast Asia Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 35：Australia Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 36：Latin America Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 37：Latin America Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2026 VS 2033)
Figure 38：Mexico Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 39：Brazil Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 40：Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 41：Middle East and Africa Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2026 VS 2033)
Figure 42：Saudi Arabia Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 43：South Africa Anti-Obesity Prescription Drugs Market Revenue and Forecast (2021-2033) & (Million USD)
Figure 44：Research Methodology
Figure 45：Primary Sources
Figure 46：Data Cross Validation
English
Related Reports 
